Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035121 | 0.98 | PPARG (0.41) | PPARGPPARATSHRGCGRKDM4E | |
| SCHEMBL6035713 | 0.97 | PPARG (0.43) | PPARGPPARATSHRGCGRPPARD | |
| SCHEMBL1633062 | 0.97 | PPARG (0.41) | PPARGPPARAGCGRKDM4ELMNA | |
| SCHEMBL6036277 | 0.94 | PPARG (0.41) | PPARGPPARATSHRGCGRPPARD | |
| SCHEMBL6035183 | 0.94 | PPARG (0.41) | PPARGPPARATSHRGCGRKDM4E | |
| SCHEMBL6036123 | 0.94 | PPARG (0.43) | PPARGPPARAGCGRKDM4ELMNA | |
| SCHEMBL6035914 | 0.92 | PPARG (0.43) | PPARGPPARAGCGRPPARDFFAR1 | |
| SCHEMBL6036027 | 0.92 | PPARG (0.39) | PPARGPPARAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6036409 | 0.92 | PPARG (0.43) | PPARGPPARAGCGRKDM4ELMNA | |
| SCHEMBL6036252 | 0.91 | PPARG (0.42) | PPARGPPARATSHRGCGRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885PPARA 1717/4885TSHR 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.